|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
8.160 -0.330 (-3.887%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 29,009,254 | 31,450,109 | 30,936,904 | 27,866,870 |
| Cost of Sales | -- | -- | (8,710,543) | (9,273,423) | (8,680,490) | (6,731,776) |
| Gross Profit | -- | -- | 20,298,711 | 22,176,686 | 22,256,414 | 21,135,094 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | 32,861 | 48,065 | 37,365 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | (89,474) | (54,196) | (15,395) | 22,443 | |
| Profit / (Loss) before Taxation | -- | -- | 5,578,726 | 7,389,372 | 7,582,261 | 6,847,096 | |
| Taxation | -- | -- | (1,239,901) | (1,316,679) | (1,350,211) | (1,158,972) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | -- | -- | (10,790) | (199,368) | (140,660) | (82,939) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,882,108 | -10.303% | 4,328,035 | 5,873,325 | 6,091,390 | 5,605,185 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | (188,824) | (233,985) | (217,637) | (175,576) |
| Depreciation & Amortisation | -- | -- | 1,339,450 | 1,117,490 | 1,047,939 | 865,471 |
| Directors' Emoluments | -- | -- | 29,638 | 84,048 | 73,648 | 54,944 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 33.980 | -7.838% | 36.870 | 49.470 | 51.110 | 46.890 |
| DPS (cts) | 25.524 | -- | 23.927 | 25.399 | 18.386 | 14.959 |
| Dividend Payout Ratio (%) | 75.116% | -- | 64.896% | 51.342% | 35.973% | 31.902% |
| Cash flow per share ($) | -- | -- | 0.386 | 0.352 | 0.640 | 0.388 |
| NBV per share ($) | -- | -- | 2.772 | 2.789 | 2.531 | 2.175 |
| Remarks: | Real time quote last updated: 26/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,882,108 |
| %Change | -10.303% |
| EPS / (LPS) | RMB 0.340 |
| NBV Per Share (¥) | RMB -- |